PET/CT in malignant melanoma: Contrast-enhanced CT versus plain low-dose CT

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 5, 2011, Pages 822-831

  Pfluger, Thomas ^a   Melzer, Henriette Ingrid ^a   Schneider, Vera ^a   La Fougere, Christian ^a   Coppenrath, Eva ^a   Berking, Carola ^b   Bartenstein, Peter ^a   Weiss, Mayo ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Contrast enhanced PET CT; Malignant melanoma; Metastases; Non contrast enhanced PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MALE; MELANOMA; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; SENSITIVITY AND SPECIFICITY; SPLEEN TUMOR;

ADULT; AGED; AGED, 80 AND OVER; CONTRAST MEDIA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIATION DOSAGE; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79953678364     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-010-1702-z     Document Type: Article

References (43)

1. C Garbe A Hauschild M Volkenandt D Schadendorf W Stolz RD Kortmann, et al. 2006 Brief guidelines: malignant melanoma of the skin J Dtsch Dermatol Ges 4 344 349 16638065 10.1111/j.1610-0387.2006.05891.x (Pubitemid 44139136)
2. C Garbe A Hauschild M Volkenandt D Schadendorf W Stolz U Reinhold, et al. 2007 Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma Melanoma Res 17 393 399 17992123 10.1097/CMR.0b013e3282f05039 (Pubitemid 350084995)
3. TF Hany HC Steinert GW Goerres A Buck GK von Schulthess 2002 PET diagnostic accuracy: improvement with in-line PET-CT system: initial results Radiology 225 575 581 12409597 10.1148/radiol.2252011568 (Pubitemid 35239264)
4. G Antoch N Saoudi H Kuehl G Dahmen SP Mueller T Beyer, et al. 2004 Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET J Clin Oncol 22 4357 4368 15514377 10.1200/JCO.2004.08.120 (Pubitemid 41185156)
5. R Nutt 2002 1999 ICP Distinguished Scientist Award. The history of positron emission tomography Mol Imaging Biol 4 11 26 14538045 10.1016/S1095-0397(00)00051-0 (Pubitemid 34272707)
6. KP Friedman RL Wahl 2004 Clinical use of positron emission tomography in the management of cutaneous melanoma Semin Nucl Med 34 242 253 15493002 10.1053/j.semnuclmed.2004.06.001 (Pubitemid 39361036)
7. D Fuster S Chiang G Johnson LM Schuchter H Zhuang A Alavi 2004 Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma? J Nucl Med 45 1323 1327 15299056 (Pubitemid 47618530)
8. R Kumar A Alavi 2005 Clinical applications of fluorodeoxyglucose-positron emission tomography in the management of malignant melanoma Curr Opin Oncol 17 154 159 15725921 10.1097/01.cco.0000152626.98124.3a (Pubitemid 40516284)
9. D Rinne RP Baum G Hör R Kaufmann 1998 Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients Cancer 82 1664 1671 9576286 10.1002/(SICI)1097-0142(19980501)82:9<1664::AID- CNCR11>3.0.CO;2-2 1:STN:280:DyaK1c3jsFyiuw%3D%3D (Pubitemid 28208915)
10. F Jiménez-Requena RC Delgado-Bolton C Fernández- Pérez SS Gambhir J Schwimmer JM Pérez-Vázquez, et al. 2009 Meta-analysis of the performance of (18)F-FDG PET in cutaneous melanoma Eur J Nucl Med Mol Imaging 37 284 300 19727717 10.1007/s00259-009-1224-8
11. B Krug M Dietlein W Groth H Stützer T Psaras A Gossmann, et al. 2000 Fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant melanoma. Diagnostic comparison with conventional imaging methods Acta Radiol 41 446 452 11016764 1:STN:280:DC%2BD3cvmtl2gtg%3D%3D
12. JD Wagner DS Schauwecker D Davidson S Wenck SH Jung G Hutchins 2001 FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume J Surg Oncol 77 237 242 11473371 10.1002/jso.1102 1:STN:280: DC%2BD3MvisFCmuw%3D%3D (Pubitemid 32744191)
13. SA Gulec MB Faries CC Lee D Kirgan C Glass DL Morton, et al. 2003 The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making Clin Nucl Med 28 961 965 14663316 10.1097/01.rlu.0000099805.36471.aa (Pubitemid 38281828)
14. J Horn H Sjøstrand J Lock-Andersen A Loft 2010 PET scanning for malignant melanoma and positive sentinel node diagnostics Ugeskr Laeger 172 1126 1130 20427004
15. T Beyer DW Townsend T Brun PE Kinahan M Charron R Roddy, et al. 2000 A combined PET/CT scanner for clinical oncology J Nucl Med 41 1369 1379 10945530 1:STN:280:DC%2BD3cvitFCguw%3D%3D (Pubitemid 30643379)
16. J Czernin M Allen-Auerbach HR Schelbert 2007 Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006 J Nucl Med 48 78S 88S 17204723 1:CAS:528:DC%2BD2sXitVamsrw%3D (Pubitemid 47604945)
17. FM Mottaghy C Sunderkötter R Schubert P Wohlfart NM Blumstein B Neumaier, et al. 2007 Direct comparison of [(18)F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma Eur J Nucl Med Mol Imaging 34 1355 1364 17295038 10.1007/s00259-006-0358-1 (Pubitemid 47312575)
18. MJ Reinhardt AY Joe U Jaeger A Huber A Matthies J Bucerius, et al. 2006 Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients J Clin Oncol 24 1178 1187 16505438 10.1200/JCO.2005.03.5634 (Pubitemid 46638816)
19. G Antoch M Forsting 2004 How much CT does PET/CT need? Nuklearmedizin 43 141 142 15480501 1:STN:280:DC%2BD2crhtVyhtA%3D%3D (Pubitemid 39456601)
20. G Antoch LS Freudenberg T Beyer A Bockisch JF Debatin 2004 To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT J Nucl Med 45 56S 65S 14736836 1:CAS:528:DC%2BD2cXht1arur8%3D
21. H Kuehl G Antoch 2005 How much CT do we need for PEt/CT? A radiologist's perspective Nuklearmedizin 44 S24 S31 16395975
22. K Strobel CM Thuerl TF Hany 2005 How much intravenous contrast is needed in FDG-PET/CT? Nuklearmedizin 44 S32 S37 16395976
23. MA Nading CM Balch AJ Sober 2010 Implications of the 2009 American Joint Committee on Cancer Melanoma Staging and Classification on dermatologists and their patients Semin Cutan Med Surg 29 142 147 21051007 10.1016/j.sder.2010.06. 004 1:CAS:528:DC%2BC3cXhtlyksbfN
24. C Müller-Horvat P Radny TK Eigentler J Schäfer C Pfannenberg M Horger, et al. 2006 Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma Eur J Cancer 42 342 350 16364631 10.1016/j.ejca.2005.10.008 (Pubitemid 43132889)
25. B Krug R Crott I Roch M Lonneux C Beguin JF Baurain, et al. 2010 Cost-effectiveness analysis of FDG PET-CT in the management of pulmonary metastases from malignant melanoma Acta Oncol 49 192 200 20059314 10.3109/02841860903440254
26. MJ Gollub R Hong DM Sarasohn T Akhurst 2007 Limitations of CT during PET/CT J Nucl Med 48 1583 1591 17873133 10.2967/jnumed.107.043109 (Pubitemid 47572704)
27. AC Buzaid L Tinoco MI Ross SS Legha RS Benjamin 1995 Role of computed tomography in the staging of patients with local-regional metastases of melanoma J Clin Oncol 13 2104 2108 7636554 1:STN:280:DyaK2MzmtlCqtQ%3D%3D
28. GJ Cook EA Wegner I Fogelman 2004 Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging Semin Nucl Med 34 122 133 15031812 10.1053/j.semnuclmed.2003.12.003 (Pubitemid 38375467)
29. SJ Rosenbaum T Lind G Antoch A Bockisch 2006 False-positive FDG PET uptake-the role of PET/CT Eur Radiol 16 1054 1065 16365730 10.1007/s00330-005- 0088-y
30. TS Aukema RA Valdés Olmos MW Wouters WM Klop BB Kroon WV Vogel, et al. 2010 Utility of preoperative 18F-FDG PET/CT and brain MRI in melanoma patients with palpable lymph node metastases Ann Surg Oncol 17 2773 2778 20422454 10.1245/s10434-010-1088-y
31. K Strobel R Dummer DB Husarik M Pérez Lago TF Hany HC Steinert 2007 High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases Radiology 244 566 574 17641374 10.1148/radiol.2442061099 (Pubitemid 47080890)
32. P Veit-Haibach FM Vogt R Jablonka H Kuehl A Bockisch T Beyer, et al. 2009 Diagnostic accuracy of contrast-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma Eur J Nucl Med Mol Imaging 36 910 918 19156409 10.1007/s00259-008-1049-x
33. J Klode J Dissemond S Grabbe U Hillen T Poeppel C Boeing 2010 Sentinel lymph node excision and PET-CT in the initial stage of malignant melanoma: a retrospective analysis of 61 patients with malignant melanoma in American Joint Committee on Cancer stages I and II Dermatol Surg 36 439 445 20187901 10.1111/j.1524-4725.2010.01479.x 1:CAS:528:DC%2BC3cXltFSrtrg%3D
34. C la Fougère T Pfluger V Schneider M Hacker N Bröckel D Morhard, et al. 2008 Restaging of patients with lymphoma. Comparison of low dose CT (20 mAs) with contrast enhanced diagnostic CT in combined [(18)F]-FDG PET/CT Nuklearmedizin 47 37 42 18278211 (Pubitemid 351272809)
35. AC Pfannenberg P Aschoff K Brechtel M Müller M Klein R Bares, et al. 2007 Value of contrast-enhanced multiphase CT in combined PET/CT protocols for oncological imaging Br J Radiol 80 437 445 17329683 10.1259/bjr/34082277 1:STN:280:DC%2BD2svmtlWqtA%3D%3D (Pubitemid 47322230)
36. U Tateishi T Maeda T Morimoto M Miyake Y Arai EE Kim 2007 Non-enhanced CT versus contrast-enhanced CT in integrated PET/CT studies for nodal staging of rectal cancer Eur J Nucl Med Mol Imaging 34 1627 1634 17530248 10.1007/s00259-007-0455-9 (Pubitemid 47476922)
37. AC Pfannenberg P Aschoff K Brechtel M Müller R Bares F Paulsen, et al. 2007 Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer Eur J Nucl Med Mol Imaging 34 36 44 16896664 10.1007/s00259-006- 0186-3 (Pubitemid 44885552)
38. B Rodríguez-Vigil N Gómez-León I Pinilla D Hernández-Maraver J Coya L Martín-Curto, et al. 2006 PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT J Nucl Med 47 1643 1648 17015900 (Pubitemid 47545030)
39. G Brix U Lechel G Glatting SI Ziegler W Münzing SP Müller, et al. 2005 Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations J Nucl Med 46 608 613 15809483 1:CAS:528: DC%2BD2MXjvVyqtLw%3D (Pubitemid 41716405)
40. SK Morcos HS Thomsen 2001 Adverse reactions to iodinated contrast media Eur Radiol 11 1267 1275 11471623 10.1007/s003300000778 1:STN:280: DC%2BD38%2FitlCqtg%3D%3D (Pubitemid 32821379)
41. AJ van der Molen HS Thomsen SK Morcos Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR) 2004 Effect of iodinated contrast media on thyroid function in adults Eur Radiol 14 902 907 14997334 10.1007/s00330-004-2238-z (Pubitemid 38678914)
42. V Laurent G Trausch O Bruot P Olivier J Felblinger D Régent 2010 Comparative study of two whole-body imaging techniques in the case of melanoma metastases: advantages of multi-contrast MRI examination including a diffusion-weighted sequence in comparison with PET-CT Eur J Radiol 75 376 383 19497694 10.1016/j.ejrad.2009.04.059
43. S Garg K Kothari SR Thopate AK Doke PK Garg 2009 Design, synthesis, and preliminary in vitro and in vivo evaluation of N-(2-diethylaminoethyl)-4-[18F] fluorobenzamide ([18F]-DAFBA): a novel potential PET probe to image melanoma tumors Bioconjug Chem 20 583 590 19222206 10.1021/bc8005094 1:CAS:528: DC%2BD1MXhvFGmsbw%3D